IC Targets
About edit
IC Targets AS (Norwegian Contrasts) is a Norwegian life science company developing novel MRI contrast agents based on manganese chemistry. Founded in 2002, making it one of the oldest companies in the NHT cluster.
Technology edit
The company's core innovation is manganese-based MRI contrast agents. Conventional MRI contrast agents are based on gadolinium, which has raised safety concerns due to deposition in brain tissues and kidneys. Manganese is a naturally occurring mineral (essential trace element) that can serve as an alternative MRI contrast agent, potentially offering improved safety profiles.
Market Need edit
Gadolinium-based contrast agents are used in approximately 30-50% of MRI examinations globally. Growing concerns about gadolinium retention in the brain and other tissues have created interest in alternative contrast technologies. A manganese-based agent that maintains diagnostic efficacy while reducing safety concerns would address a significant market need.